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Abstract
Since the end of the last century resistance to oxyimino b-lactams has steadily increased in Enterobacteriaceae. In the present work we
studied extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae strains isolated in the teaching hospital of Clermont-Ferrand,
France, between 2006 and 2009. A total of 1368 ESBL-producing isolates were collected. Most of these isolates (69%) were
CTX-M-producing Escherichia coli. During the study, the clinical incidence increased by more than 400%, even in the emergency department,
and especially in community-acquired infections, as is the case elsewhere in the world. Most of the ESBL-producing isolates remained
susceptible to furans and fosfomycin, but only 50% to fluoroquinolons. In conclusion, ESBL-producing bacteria constantly increased during
the study period. Unlike many studies, this increase was associated with the wide dissemination of three different CTX-M enzymes:
CTX-M-14, CTX-M-15 and CTX-M-1.
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Introduction
ß-Lactams are currently the main antibacterial agents used in
medicine because of their bactericidal effect, low toxicity and
broad spectrum of efficiency. However, their increasing use
has led to the emergence of extended spectrum b-lactamase
(ESBL)-producing strains. These enzymes confer resistance to
penicillins, cephalosporins and oxyimino b-lactams (such as
cefotaxime), but remain susceptible to b-lactamase inhibitors
and inactive against carbapenems and cephamycins [1]. The
first ESBLs were identified during the 1980s. They belonged to
the TEM and SHV b-lactamase families. These ESBLs were
produced by nosocomial strains, in particular Klebsiella pneu-
moniae and Enterobacter sp., and were mainly observed in
intensive care units [2,3]. Since the middle of the 1990s new
ESBLs, designated CTX-M, have appeared within Enterobac-
teriaceae strains worldwide [4–6]. These enzymes were mainly
observed in Escherichia coli strains, which are now found in
both hospitals and the community [7,8]. The spread of these
resistant bacteria has resulted in a frequent use of carbapen-
ems, which were kept as a drug of last resort to combat
multidrug-resistant Enterobacteriaceae [9,10].
To assess the diffusion of these widespread CTX-M
enzymes, we performed a retrospective study of ESBL-pro-
ducing Enterobacteriaceae in the French teaching hospital of
Clermont-Ferrand, France, between 2006 and 2009.
Materials and Methods
All ESBL-producing strains isolated from 1 January 2006 to 31
December 2009 in the microbiological laboratory of the
teaching hospital of Clermont-Ferrand were included. This
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hospital has about 2000 beds and 61 wards, with almost
550 000 hospitalization days and 650 000 consultations in
2009.
Bacterial isolates
Identification and susceptibility testing were performed using
GN cards for identification, and AST-N103 and EXN8 cards
(Vitek2 system, BioMerieux, Lyon, France) for Enterobacte-
riaceae susceptibility testing according to the manufacturer’s
recommendations (Biomerieux). ESBL-producing strains were
detected by decreased susceptibility to oxyimino cephalospo-
rin using a breakpoint of 1 lg/mL for cefotaxime, ceftriaxone
and ceftazidime throughout the whole study.
ESBL confirmation tests
Extended-spectrum b-lactamase-producing strains were con-
firmed by the double-disk-diffusion test (synergy test) as
recommended by the Comite de l’antibiogramme of the
French Society of Microbiology [11]. Antibiotic disks contain-
ing cefotaxime (30 lg), ceftazidime (30 lg) or cefepime
(30 lg) were placed on a plate, 30 mm (centre to centre)
from a disc of amoxycillin-clavulanate (20/10 lg). The interdisk
distance was increased to 40–45 mm for Proteus and Providen-
cia isolates, as recommended. After overnight incubation at
37°C, an increase in the edge of an antimicrobial inhibition
zone towards the disk containing clavulanate was considered
to indicate synergy and hence the production of an ESBL.
b-Lactamases were further investigated by isoelectric
focusing as previously described [12] and finally identified by
specific PCR and sequencing experiments using specific
primers as previously described [13].
Epidemiological data
Patient data, clinical departments, ESBL-producing bacterial
species and their content in b-lactamase were extracted from
the software of the microbiological laboratory (Inlog, Brain-
tree, United Kingdom). Duplicates corresponding to the same
strain found in the same patient were deleted. The teaching
hospital’s clinical departments comprise the intensive care,
emergency, after care, haematology, maternity, medicine,
pediatric, psychiatry and surgery units. There also exists a
cancer unit with outpatients. Only intensive care, haematology,
surgery and cancer units collected screening samples for the
detection of colonization of ESBL producers.
Finally, to establish the incidence of ESBL-producing strains
(number of new ESBL-producing strains in relation to 1000
hospitalization days (HD)), the number of hospitalization days
for the 4-year period was provided by the administrative staff
of the hospital. Relative risks were calculated with a 95%
confidence interval.
Antimicrobial resistance rates
Susceptibility testing results were extracted from the software
management of the laboratory and then analysed for the
4 years of the study. All the antibiotic susceptibilities were
interpreted following the 2009 French recommendations [11].
The ‘multidrug resistance’ character of the ESBL-producing
strains was defined on the basis of resistance to three
antibiotic families [14,15]. Various antibiotic susceptibility
percentages were analysed for each year with the chi-square
test to detect significant differences in the susceptibility of
ESBL-producing strains.
Results
Prevalence of ESBL production
Six hundred and ninety-nine new ESBL-producing strains were
detected, with an increase from 1.04% of Enterobacteriaceae
(n = 7183) in 2006 to 8.45% (n = 8282) in 2009. ESBLs have
mainly been found in E. coli and Klebsiella sp., which respec-
tively represented 79.2% and 11.2% of ESBL-producing isolates
over the 4-year study period. The ESBL percentage of E. coli
increased significantly, from 1.25% in 2006 to 9.35% in 2009
(p <0.001). For clinical samples this ESBL percentage within
E. coli increased from 0.9% to 6.3%. Similarly, the percentage of
ESBL-producing Klebsiella sp. increased from 2.7% in 2008 to
16% in 2009 (p <0.001). ESBLs have also been isolated in other
Enterobacteriaceae such as Enterobacter (4.1% of ESBL-pro-
ducing isolates), Proteus (2.6%), Citrobacter (1.4%), Salmonella
(0.4%), Morganella (0.3%) and Providencia (0.1%), without any
increase over the study period. Thus, the relative risk (RR) of
strains acquiring an ESBL was greater in the case of E. coli
(RR = 2.54 (2.14; 3.01)) and Klebsiella (RR = 2.02 (1.59; 2.58)).
Most ESBLs were CTX-M enzymes (84.9%), with a signif-
icant increase between 2006 and 2009 (74.6% vs. 89.3%,
p <0.05). Three predominant ESBLs were isolated: CTX-M-14
(31.7%), CTX-M-15 (28.5%) and CTX-M-1 (23.5%). The other
ESBLs found were TEM enzymes (12.3%) (TEM-3, TEM-19 and
TEM-24 mainly) and SHV enzymes (2.8%) (SHV-2 and SHV-12),
without any significant change in the number of isolates during
the study period.
Epidemiological data and risk factor for acquiring ESBL
There was no significant difference between men and women in
the risk of acquiring an ESBL-producing strain (sex ratio = 1.18).
The risk of patients being infected by an ESBL-producing isolate
increased with age, to a level of significance for patients over
65 years old (RR = 1.25 (1.09; 1.46)). The large majority of
positive samples for ESBL-producing strains were of urinary
(38.3%) and digestive origin (37.6%; including screening
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samples for ESBL-producing microorganisms). Urinary tract
infections were the predominant suppliers of ESBL producers
because ESBL producers isolated from urine samples
accounted for 61.5% of clinical samples. ESBL producers were
also isolated from blood (10.8%), skin (7.9%) and respiratory
samples (5%), from biopsy and deep samples (4.5%) and from
neonatal samples (2.6%).
The percentage of ESBL-producing strains increased signif-
icantly (p <0.05) between 2006 and 2009 in all clinical
departments, except for the psychiatry and cancer units.
Relative risks (RRs) for each unit group showed a higher
acquisition risk in intensive care units (RR = 1.78 (1.60; 2.02))
and haematological units (RR = 3.07 (2.79; 3.05)), in both
clinical and screening samples.
Because many ESBL producers have been identified from
rectal swabbing samples, we focused on ESBL-producing
strains that had been isolated in clinical samples (n = 439).
We established the clinical incidence of ESBLs as the number
of new ESBL-producing strains isolated from clinical samples
per year relative to 1000 hospitalization days (HD). This
incidence increased by over 400% (0.391 cases/1000 hospi-
talization days in 2009 vs. 0.092 in 2006) and exceeded 1
case/1000 hospitalization days in intensive care units and
emergency departments (Figs 1 and 2, Table 1). The inci-
dence in 2006, 2007 and 2008 was lower but in 2009 was
greater than the mean overall incidence in 333 health
institutions that collaborated in a national BMR-Raisin
network [16]. These findings also correlate with increased
ESBL incidence in Europe [7]. The distribution of different
ESBL producers was unchanged in various unit groups. The
three predominant enzymes (CTX-M-14, CTX-M-15 and
CTX-M-1) were found in isolates from all clinical unit groups
each year, except psychiatry where few ESBL producers were
identified (Fig. 2b). In urine samples, CTX-M-14, CTX-M-15
and CTX-M-1 were observed, respectively, in 25.2%, 24.4%
and 18.3% of the strains. Otherwise, three major ESBLs were
identified from strains isolated in blood samples: E. coli and
Klebsiella pneumoniae producing CTX-M-15 (37.8%), E. coli
producing CTX-M-14 (13.3%) and E. coli producing CTX-M-1
(11.1%).
Antimicrobial resistance rates in ESBL-producing isolates
The antibiotic susceptibility of ESBL producers from screen-
ing or clinical samples is shown in Table 2. About 50% of
ESBL producers remained susceptible to fluoroquinolons,
40% to trimetoprime-sulphamethoxazole, and over 70% to
aminoglycosides. There is no significant difference in antibi-
otic susceptibility for screening samples between 2006 and
2009. Nevertheless, we noticed a higher susceptibility of
ESBL-producing strains to gentamicin in 2009 than in 2006,
and the inverse for amikacin, in a significant way for clinical
samples.
The combinations of penicillins with b-lactamase inhibitors
such as piperacillin/tazobactam are frequently active against
ESBL producers, with 79.8% susceptibility for E. coli and 83.3%
for Proteus in 2009. However, we observed a significant
decrease in the effectiveness of piperacillin/tazobactam
between 2006 and 2009 for clinical samples (90.9% vs. 72.1%
of susceptibility, p <0.05).
During the study period, 76.7% of ESBL-producing strains
isolated from screening or clinical samples remained suscep-
tible to cefoxitin, and 52.6% to at least one oxyimino
cephalosporin (which is currently recommended in France for
uncomplicated infections with susceptible ESBL producers),
mostly ceftazidime. In addition, 99.8% of ESBL producers
were susceptible to carbapenems (100% in 2006 and 99.7% in
2009), which remain the reference treatment for infections
caused by ESBL-producing bacteria. The carbapenems tested
were imipenem, meropenem and ertapenem. We detected in
2009 three strains of ertapenem-resistant Enterobacter cloa-
cae, which did not produce a carbapenemase: one from a
screening sample and two from clinical samples. Other less
frequently used antibiotics are still effective against ESBL-pro-
ducing strains, such as colistin (97.7% of susceptible strains)
for all Enterobacteriaceae (including Proteus and Morganella)
and tigecyclin (99.5% of susceptible strains) for E. coli only.
Tigecyclin was less effective against other strains (36.5% of
susceptibility, excluding Proteus mirabilis). The percentage of
multiresistant ESBL producers did not increase during the
study period, but still remained high, accounting on average
for 68.2% of strains.
As ESBL-producing Enterobacteriaceae are mainly isolated
from the urinary tract, we focused on antibiotics used in lower
urinary tract infections and on ESBL producers isolated from
clinical samples. In France and Europe, the two recommended
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FIG. 1. Incidence of extended-spectrum b-lactamase (ESBL) between
2006 and 2009 in Clermont-Ferrand’s Hospital and comparison with
national incidence (BMR-raisin, national network) (HD = hospitaliza-
tion days).
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antibiotics are fosfomycin and nitrofurans [17]. In the USA,
trimethoprim-sulphamethoxazole is also recommended [18].
In the present study, only 32.3% of ESBL producers were still
susceptible to trimethoprim-sulphamethoxazole (n = 412).
However, fosfomycin and nitrofurans are, respectively, effec-
tive against 89.6% (n = 29) and 70.4% (n = 405) of ESBL-pro-
ducing strains.
Discussion
Prevalence of ESBL production
The number of ESBL-producing strains significantly increased
between 2006 and 2009 at Clermont-Ferrand, as elsewhere in
France and worldwide [5]. Two species of Enterobacteriaceae
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TABLE 1. Relative risk of acquisition of extended-spectrum b-lactamase (ESBL) producers and clinical incidence per clinical unit
Clinical units Relative risk Confidence interval 0.95
Incidence of ESBL
2006 2007 2008 2009
Emergency 0.46 0.36–0.59 0.577 1.011 0.644 1.132
Intensive care 1.78 1.60–2.02 0.451 0.315 0.614 1.093
Medicine 0.67 0.58–0.77 0.105 0.121 0.263 0.504
Surgery 0.97 0.85–1.11 0.067 0.068 0.199 0.398
Paediatrics 0.6 0.39–0.91 0.126 0.08 0.123 0.664
Haematology 3.07 2.79–3.65 0.207 0.456 0.553 0.748
Maternity 0.43 0.31–0.61 0.037 0.145 0.181 0.595
Psychiatry 1.35 0.64–2.91 0 0 0.034 0.035
After care 0.79 0.55–1.11 0.023 0.008 0.065 0.074
Total incidence 0.092 0.108 0.199 0.391
Bold values indicate significant difference.
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are especially affected, E. coli and K. pneumoniae. In our study,
79.2% of ESBL-producing isolates, by far the majority, were
found in E. coli, a finding that indicates the significant evolution
in species distribution within ESBL-producing strains. In
comparison, E. coli accounted for only 8% of ESBL-producing
strains in 2000, according to a French network of resistance
monitoring [14].
The CTX-M encoding genes transferred from environmen-
tal Kluyvera strains to pathogenic microorganisms including
E. coli via insertion sequences [4,19]. These genes then spread
worldwide, due, in part, to the existence of many reservoirs.
The gut microbiota of healthy humans and animals can contain
ESBL producers [20–22] and they have also been detected in
the environment, in wastewater from hospitals, and in river
and sea water [23,24]. ESBL producers may also be present in
protozoa in the rumen of animals and in natural environments
[25]. The dissemination of ESBL producers in the community
explains the current, significant increase in ESBL-producing
E. coli, which reached almost 10% of isolated E. coli in our
teaching hospital in 2009. Unlike for E. coli, the increase in
ESBL-producing K. pneumoniae is mainly due to the dissemi-
nation of a clonal strain of CTX-M-15-producing K. pneumo-
niae associated with gastrointestinal endoscopy [26]. Other
invasive acts had also been responsible for the spread of ESBL
producers [27].
The main enzymes characterized during this study were
CTX-M enzymes, including CTX-M-14, CTX-M-15 and
CTX-M-1. The CTX-M-15 enzyme is also found everywhere
in Europe, unlike CTX-M-14 and CTX-M-1, which have been
isolated in Spain, Italy and Belgium [6].
In contrast, the number of TEM and SHV enzymes remained
stable during our study period, as a result of the effective
control of the dissemination of TEM and SHV enzymes in
hospitals and the community since the 1990s.
Epidemiological data and risk factor for having ESBL
We found no significant difference in ESBL-producing isolate
acquisition between genders, unlike other studies, which
observed a higher risk of ESBL producers in males [28]; this
can be explained by the greater number of ESBL-producing
isolates from urinary tract infections, which are more frequent
in women. We found a higher relative risk in patients over
65 years old, as shown previously. This increased risk may be
explained by an age-related increase in susceptibility to
infection, which probably led to ESBL-selecting antibiotic use
[29].
The clinical incidence of ESBL producers also significantly
increased during our study. We observed a raised incidence in
many clinical departments, including the haematological and
intensive care units, where the most fragile patients are to be
found. However, we also found a sharply increased incidence
of ESBL producers in emergency departments, due to the
diffusion of ESBL producers in the community. In addition, we
observed a large variety of enzymes, including in intensive care
units, suggesting the dissemination of different strains. How-
ever, CTX-M-14, CTX-M-15 and CTX-M-1 were the most
frequent enzymes found in all hospital units. There could have
been an epidemic spread of their genetic support or of several
clones, which is surprising because these three enzymes were
equally distributed in our hospital, unlike in the rest of France
and more generally in Europe, where CTX-M-15 is largely
dominant [6].
Antimicrobial resistance rates in ESBL-producing isolates
The antimicrobial susceptibility testing study has shown a
decrease since 2006 in susceptibility to b-lactam antibiotics,
especially piperacillin/tazobactam, which are normally effective
against ESBL-producing strains. In addition, we observed a
slight decrease in carbapenem susceptibility. The reduced
efficacy of carbapenems, due to porin changes or carbape-
nemase production, is a new challenge for the management of
Enterobacteriaceae infections, because the alternatives avail-
able are very limited. Furthermore, carbapenemases have a
strong scattering power and are already endemic in some
countries [30]. The detection of these new enzymes is very
important, especially for patients who have resided in endemic
areas, in order to implement hygiene measures to limit their
dissemination [31].
TABLE 2. Antibiotic susceptibility of extended-spectrum b-lactamase (ESBL) producers from screening and clinical samples in
2006 and 2009
Antibiotic
Screening samples Clinical samples
% of susceptibility in
2006
% of susceptibility in
2009 v² p
% of susceptibility in
2006
% of susceptibility in
2009 v² p
Piperacillin/tazobactam 0.85 0.7 1.93 0.2 0.909 0.721 6.92 <0.01
Carbapenems 1 0.995 0.08 >0.5 1 0.995 0.21 >0.5
Amikacin 0.85 0.75 0.96 0.5 0.826 0.663 4.67 <0.05
Gentamicin 0.75 0.808 0.36 >0.5 0.644 0.787 4 <0.05
Ciprofloxacin 0.421 0.592 1.93 0.2 0.533 0.462 0.76 0.5
Trimethoprim-sulphamethoxazole 0.35 0.367 0.02 >0.5 0.364 0.293 0.85 0.5
Bold values indicate significant difference.
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For the other families of antimicrobial agents, we found a
different phenotype of aminoglycoside resistance, with a higher
susceptibility to amikacin in 2006 and gentamicin in 2009.
With regard to antibiotics used in urinary tract infections,
the poor effectiveness of trimethoprim-sulphamethoxazole
justifies the European recommendations not to use it as a
first-line treatment. We also observed a good susceptibility of
ESBL strains to furans and fosfomycin, two first-line antibiotics
used in Europe in low urinary tract infections.
Conclusion
Extended-spectrum b-lactamase-producing Enterobacteria-
ceae are constantly increasing in number in our hospital,
regardless of patient age or clinical department, including units
previously spared such as the emergency department. Most
characterized enzymes are CTX-M, but unlike in other
hospitals where CTX-M-15 is largely predominant, we
observed three predominant CTX-M enzymes: CTX-M-15,
CTX-M-14 and CTX-M-1.
Most ESBL-producing strains remain fairly susceptible to
many antibiotics but we observed a worrying reduced efficacy
of piperacillin-tazobactam. Consequently, alternative anti-
microbial agents to b-lactams will be required to treat
Enterobacteriaceae infections.
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